ImmunityBio(IBRX)
$6.67-0.08 (-1.11%)
IBRX
ImmunityBio Revenue
$6.67
At close:-0.08 (-1.11%)
Want to see IBRX full AI Analyst Report?
ImmunityBio (IBRX) Revenue
2,633 Followers
ImmunityBio Revenue
ImmunityBio had a revenue of 48.84M in the quarter ending Sep 30, 2026, with -4.68%. This bring the company's revenue in the last twelve months to 182.57M, Increased 10.12%. In the fiscal year ending Dec 31, 2025, ImmunityBio had annual revenue of 113.29M with 668.31% growth.
- Revenue (ttm)
- 182.57M
- Revenue Growth
- 121.15%
- P/S Ratio
- 63.34
- Revenue/Employee
- $164,663
- Employees
- 688
- Market Cap
- $7.18B
Revenue Chart
ImmunityBio Revenue - Annual
Revenue History
| Fiscal End Date | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 113.29M | 98.54M | 668.31% |
| Dec 31, 2024 | 14.74M | 14.12M | 2270.58% |
| Dec 31, 2023 | 622.00K | 382.00K | 159.17% |
| Dec 31, 2022 | 240.00K | -694.00K | -74.30% |
| Dec 31, 2021 | 934.00K | 329.00K | 54.38% |
| Dec 31, 2020 | 605.00K | 562.00K | 1306.98% |
| Dec 31, 2019 | 43.00K | -4.00K | -8.51% |
| Dec 31, 2018 | 47.00K | 2.00K | 4.44% |
| Dec 31, 2017 | 45.00K | ― | ― |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.